medigraphic.com
ISSN 1561-3011 (Electronic)

2021, Number 1

<< Back Next >>

Rev Cubana Invest Bioméd 2021; 40 (1)

Synergic effect of a biphosphonate with vitamin D

Velazquez DJA, Morales ERI

Language: Spanish
References: 57
Page: 1-14
PDF size: 523.33 Kb.


ABSTRACT

Introduction: Biphosphonates are considered to be a group of very useful drugs used to treat osseous tissue conditions, since they foster resorption. They are first line in the treatment of osteoporosis, Paget's disease, multiple myeloma and malignant hypercalcemia. Vitamin D, on the other hand, is an essential nutrient whose main function is calcium (Ca+2) and phosphate (P4 3-) homeostasis.
Objective: Describe the molecular and pharmacological aspects of the action of a biphosphonate (alendronate sodium) and vitamin D on osseous diseases.
Methods: A selection was made of the most updated references about relevant aspects of alendronate and vitamin D. The databases consulted were Pubmed, Uniprot and Protein Databank.
Conclusions: The synergy between alendronate and vitamin D generates beneficial effects on osseous tissue. However, their use should be controlled, since side-effects may affect other tissues.


REFERENCES

  1. Vidal MA, Medina C, Torres LM. Seguridad de los bifosfonatos. Rev Soc Esp Dolor. 2011;18(1):43-55.

  2. Hinshaw WB, DeLong AF. An Evaluative History of Bisphosphonate Drugs: Dual Physiologic Effects of Pyrophosphate as Inspiration fora Novel Pharmaceutical Class. J Osteoporos. 2016;2016:e1426279. DOI: 10.1155/2016/1426279

  3. Hawkins F, Jódar E, Martínez G. Bases moleculares del mecanismo de acción de los bifosfonatos. REEMO. 2000;9(5):169-71.

  4. DeLuca HF. History of the Discovery of vitamin D and its active metabolites. Bonekey Rep. 2014;3(479):1-8. DOI: 10.1038/bonekey.2013.213

  5. Yun H, Curtis JR, Saag K, Kilgore M, Muntner P, Smith W, et al. Generic alendronate use among Medicare beneficiaries: are Part D data complete? Pharmacoepidemiol Drug Saf. 2013;22(1):55-63. DOI: 10.1002/pds.3361

  6. Manzano F, Ramos J, Melguizo L, Illescas R, Ruiz C, García O. Bisphosphonate Modulation of the Gene Expression of Different Markers Involved in Osteoblast Physiology: Possible Implications in Bisphosphonate-Related Osteonecrosis of the Jaw. Int J Med Sci. 2018;15(4):359-67. DOI: 10.7150/ijms.22627

  7. Mendes V, Dos Santos GO, Calasans MD, Granjeiro JM, Moraschini V. Impact of bisphosphonate therapy on dental implant outcomes: An overview of systematic review evidence. Int J Oral Maxillofac surg. 2018;48(3):373-81. DOI: 10.1016/j.ijom.2018.09.006

  8. Roddy E, Muller S, Paskins Z, Hider SL, Bucknall MB, Mallen CD. Incident acute pseudogout and prior bisphosphonate use: Matched case-control study in the UK- clinical practice research datalink. Medicine (Baltimore). 2017;96(12):e6177. PMID: 28328803

  9. Ozaras N, Rezvani A. Diffuse skeletal pain after administration of alendronate. Indian J Pharmacol. 2010;42(4):245-6. DOI: 10.4103/0253-7613.68435

  10. Dieckmeyer M, Ruschke S, Rohrmeier A, Syväri J, Einspieler I, Klauss VS, et al. Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy. BMC Musculoskeletal Disorders. 2019;20:515. DOI: 10.1186/s12891-019-2916-2

  11. Sheikh Z, Chen G, Jaf F A, Thévenin M, Banks K, Glogauer M, et al. In Vivo bone effects of a novel bisphosphonate -EP4a conjugate drug (C3) for reversing osteoporotic bone loss in an ovariectomized rat model. JBMR Plus. 2019;3(12):e10237. DOI: 10.1002/jbm4.10237

  12. Hauser M, Siegrist M, Keller I, Hofstetter W. Healing of fractures in osteoporotic bones in mice treated with bisphosphonates-A transcriptome analysis. Bone. 2018;(112):107-19. DOI: 10.1016/j.bone.2018.04.017

  13. Shinkai I, Ohta Y. New Drugs-Reports of new drugs recently approved by the FDA. Bioorg Med Chem. 1996;4 (1):3-4. DOI: 10.1016/0968-0896(96)00042-9

  14. Barreira E. Antirresortivos. Ortho-tips. 2010;6(1):63-72.

  15. Machairiotis N, Ntali G, Kouroutou P, Michala L. Clinical evidence of the effect of bisphosphonates on pregnacy and the infant. Horm Mol Biol Clin Investig. 2019;40(2). DOI: 10.1515/hmbci-2019-0021

  16. Teixeira S, Branco L, Fernandes MH, Costa RJ. Bipshosphonates and Cancer: A Relationship Beyond the Antiresorptive Effects. Mini Rev Med Chem. 2019;19(12):988-98. DOI: 10.2174/1389557519666190424163044

  17. Manzano-Moreno FJ, Montes-Illescas R, Melguizo-Rodriguez L, Costela-Ruiz VJ, Garcia-Martinez O, Ruiz C, et al. Impact of bisphosphonates on the proliferation and gene expression of human fibroblast. Int J Med Sci. 2019;16(12):1534-40. DOI: 10.7150/ijms.36994

  18. Cortez-Franco F. Vitamina D y análogos. Dermatol Perú. 2014;24(1):27-33.

  19. Žmitek K, Hribar M, Hristov H, Pravst I. Efficiency of vitamin D supplementation in healthy adults in associated with body mass index and baseline serum 25-hidroxyvitamin D Level. Nutrients. 2020;12(5). DOI: 10.3390/nu12051268

  20. Ukon Y, Makino T, Kodama J, Tsukazaki H, Tateiwa D, Yoshikawa H, et al. Molecular-Based treatment strategies for osteoporosis: a literature Review. Int J Mol Sci. 2019;20(10):2557. DOI: 10.3390/ijms20102557

  21. Wintermeyer E, Ihle C, Ehnert S, Stöckle U, Ochs G, Zwart P, et al. Crucial Role of Vitamin D in the Musculoskeletal System. Nutrients. 2016;8(319):1-16. DOI: 10.3390/nu8060319

  22. Walash MI, Metwally ME, Eid M, EI-Shaheny RN. Validated spectrophotometric methods for determination of Alendronate sodium in tablet through nucleophlic aromatic substitution reactions. Chem Cent J. 2012;6(25):1-15. DOI: 10.1186/1752-153X-6-25

  23. Bikle DD. Vitamin D Metabolism, Mechanism of Action, and Clinical Applications. Chem Biol. 2014;21(3):319-29. DOI: 10.1016/j.chembiol.2013.12.016

  24. Rojas E. Osteoporosis. Rev Med Cos Cen. 2015;(615):477-81.

  25. Binkley N, Ringe JD, Reed JI, Ljunggren Ö, Holick MF, Minne HW, et al. Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: Results from the 24 weeks extension of a 15-week randomized, controlled trial. Bone. 2009;44(4):639-47. DOI: 10.1016/j.bone.2008.05.002

  26. Aisa A, Rosas M, Reza M, Díaz E, Rodríguez FL. Tratamiento de la osteoporosis en pacientes de alto riesgo: El manejo del internista. Acta Med. 2013;11(3):137-44.

  27. Zuluaga NA, Alfaro JM, Balthazar V, Jiménez KE, Campuzano G. Vitamina D: nuevos paradigmas. Medicina & Laboratorio. 2011;17(5-6): 211-46.

  28. Liao EY, Zhang ZL, Xia WB, Lin H, Cheng Q, Wang L, et al. Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium /vitamin D3 combination in Chinese women with postmenopausal osteoporosis: a post hoc efficacy analysis and safety reappraisal. BMC Musculoeskelet Discord. 2018;19(210):1-8. DOI: 10.1186/s12891-018-2090-y

  29. Straube S, Derry S, Straube C, Moore RA. Vitamin D for the treatment of chronic painful conditions in adults. Cochrane Database Syst Rev. 2015;(5):CD007771. DOI: 10.1002/14651858.CD007771.pub2

  30. Cantorna MT, Snyder L, Lin YD, Yang L. Vitamin D and 1,25 (OH)2 D Regulation of T cells. Nutrients. 2015;7(4):3011-21. DOI: 10.3390/nu7043011

  31. Miao Z, Wang S, Wang Y, Guo L, Zhang J, Liu Y, Yang Q. A potential linking between vitamin D and adipose metabolic disorders. Can J Gastroenterol Hepatol. 2020;2656321. DOI: 10.1155/2020/2656321

  32. Chuguransky SR, Cortizo AM, McCarthy AD. Alendronate can improve bone alterations in experimental diabetes by preventing antiosteogenic, antichondrogenic, and proadipocytic effects of AGEs son bone marrow progenitor cells. Biomed Res Int. 2016;1-13. DOI: 10.1155/2016/5891925

  33. Papamitsou T, Yeroyannis A M, Papanastasiou A, Bakalopoulos N, Dietrich E M, Karachrysafi S, et al. Biphosphonate’s Effect on Tongue Mucosa: An Experimental Electron Microscopu Study. Medicina (Kaunas). 2020;56(2):51.

  34. Mitchell A, Watts AE, Ebetino FH, Suva LJ. Biphosphonate use in the horse: what is good and what is not? BMC Vet Res. 2019;15:211. DOI: 10.1186/s12917-019-1966-x

  35. Berkhout J, Stone JA, Verhamme KM, Danhof M, Post TM. Disease systems analysis of bone mineral density and bone turnover markers in response to alendronate, placebo, and washout in postmenopausal women. CPT: Pharmacometrics & Syst. Pharmacol. 2016;5(12):656-64. DOI: 10.1002/psp4.12135

  36. Koiwai H, Kamimura M, Takahashi J, Nakamura Y, Kato H. Unexpected rapid increase in bone mineral density by bisphosphonate therapy after multiple spinal fractures: a case report. J Med Case Rep. 2019;13:288. DOI: 10.1186/s13256-019-2219-0

  37. Simpione G, Caldas RJ, Soares MQS, Rubira-Bullen IRF, Santos PSS. Tomographic study of Jaw bone changes in patients with bisphosphonate-related osteonecrosis. J Clin Exp Dent. 2020;12(3):e285-e290. DOI: 10.4317/jced.56265

  38. Zhang Y, Chen X, Tang Y, Lu Y, Guo L, Zhong D. Bioequivalence of generic alendronate sodium tablets (70 mg) to Fosamax® tablets (70 mg) in fasting, healthy volunteers: a randomized, open-label, three-way, reference-replicated crossover study. Drug Des Devel Ther. 2017;11:2109-19. DOI: 10.2147/DDDT.S138286

  39. Carretero M Alendronato Sódico. Offarm. 2002;21(11):138-40.

  40. Davis S, Martyn-ST M, Sanderson J, Stevens J, Goka E, Rawdin A. et al. A systematic review and economic evaluation of biphosfonates for the prevention of fragility fractures. Health Technol Assess. 2016;20(78):407-24. DOI: 10.3310/hta20780

  41. Molvik H, Khan W. Bisphosphonates and their influence on fracture healing: a systematic review. Osteoporos Int. 2015;26(4):1251-60. DOI: 10.1007/s00198-014-3007-8

  42. Meganck JA, Begun DL, McElderry JD, Swick A, Kozloff KM, Goldstein SA, et al. Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta. Bone. 2013;56(1):204-12. DOI: 10.1016/j.bone.2013.06.003

  43. Wright DH, Mols R, Brown KR, YehG C, Woolf E, Hickey L, et al. Bioequivalence of Alendronate and Vitamin D3 in a Combination Tablet Versus Corresponding-Dose Individual Tablets in Healthy Taiwanese Volunteers, determined using a novel plasma alendronate assay. Current Therapeutic Res. 2015;77:116-21. DOI: 10.1016/j.curtheres.2015.10.001

  44. Rudnick S, Corem E, Grinberg I, Yehuda R, Margel S. Near IR fluorescent conjugated poly (ethyleneglycol) bisphosphonate nano particles for in vivo bone targeting in a young mouse model. J Nanobiotechnol. 2015;13(80):1-8. DOI: 10.1186/s12951-015-0126-0

  45. Shin YH, Shin WC, Kim JW. Effect of Osteoporosis Medication on Fracture Healing: An Evidence Based Review. J Bone Metab. 2020;27(1):15-26. DOI: 10.11005/jbm.2020.27.1.15

  46. González CA, Barahona RR. Mode of action of vitamin D3, 1-α-hydroxycholecalciferol (1-α-OH-D3) and 25-hydroxycholecalciferol (25-OH-D3) in commercial laying hens. Rev CES Med Vet Zootec. 2014;9(1):114-27.

  47. Sang-Min J, Eun-Ae S. Exploring vitamin D metabolism and function in cancer. Exp Mol Med. 2018;50(4):20. DOI: 10.1038/s12276-018-0038-9

  48. Sassi F, Tamone C, D’Amelio P. Vitamin D: Nutrient, Hormone, and Inmmunomodulator. Nutrients. 2018;10(11):1656. DOI: 10.3390/nu10111656

  49. Peter C, Rodan GA. Preclinical safety profile of alendronate. Int J Clin Pract. 1999;101(Suppl):S3-S8.

  50. Zullo AR, Zhang T, Lee Y, McConeghy KW, Daiello LA, Kiel DP, et al. Effect of Bisphosphonates on Fracture Outcomes among Frail Older Adults. J Am Geriatr Soc. 2020;67(4):768-76. DOI: 10.1111/jgs.15725

  51. Marozik P, Alekna V, Rudenko E, Tamulaitiene M, Rudenka A, Mastaviciute A, et al. Bone metabolism genes variation and response to bisphosphonate treatment in women with postmenopausal osteoporosis. PLoS One. 2019;14(8):e0221511. DOI: 10.1371/journal.pone.0221511

  52. Chiu W Y, Yang W S, Chien J Y, Lee JJ, Tsai KS. The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects. PLoS One. 2018;13(4):e0196419. DOI: 10.1371/journal.pone.0196419

  53. Yu-Hung Y, Jen-Hung H, Hung-Ewn C, Yung-Kuo L, Chien-Yeh H, Yi-Jen C. Vitamin D and bisphosphonates therapies for osteoporosis are associated with different risks of atrial fibrillation in women. Medicine (Baltimore). 2018;97(43):e12947. DOI: 10.1097/MD.0000000000012947

  54. Gómez LG, González D. Possible ocular adverse effects attributable to bisphosphonate therapy: Two case reports. Rev Colomb de Reumatol. 2017;24(1):54-9. DOI: 10.1016/j.rcreue.2017.04.001

  55. Taylor PN, Davies JS. A review of the growing risk of vitamin D toxicity from inappropriate practice. Br J Clin Pharmacol. 2018;84(6):1121-7. DOI: 10.1111/bcp.13573

  56. Tarantino U, Iolascon G, Cianferotti L, Masi L, Marcucci G, Giusti F. Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology. J Orthop Traumatol. 2017;18(Suppl 1):S3-S36. DOI: 10.1007/s10195-017-0474-7

  57. Wen-Hung H, Shen-Yang L, Cheng-Hao W, Ping-Chin L. Use of Alendronate Sodium (Fosamax) to Ameliorate Osteoporosis in Renal Transplant Patients: A Case-Control Study. PLoS One. 2012;7(11):1-8. DOI: 10.1371/journal.pone.0048481




2020     |     www.medigraphic.com